Poly-L-histidine inhibits prion propagation in a prion-infected cell line

Prion. 2018;12(3-4):226-233. doi: 10.1080/19336896.2018.1505395. Epub 2018 Aug 17.

Abstract

Transmissible spongiform encephalopathies (TSEs) are a group of lethal neurodegenerative diseases involving the structural conversion of cellular prion protein (PrPC) into the pathogenic isoform (PrPSc) for which no effective treatment is currently available. Previous studies have implicated that a polymeric molecule with a repeating unit, such as pentosane polysulfate and polyamidoamide dendrimers, exhibits a potent anti-prion activity, suggesting that poly-(amino acid)s could be a candidate molecule for inhibiting prion propagation. Here, by screening a series of poly-(amino acid)s in a prion-infected neuroblastoma cell line (GTFK), we identified poly-L-His as a novel anti-prion compound with an IC50 value of 1.8 µg/mL (0.18 µM). This potent anti-prion activity was specific to a high-molecular-weight poly-L-His and absent in monomeric histidine or low-molecular-weight poly-L-His. Solution NMR data indicated that poly-L-His directly binds to the loop region connecting Helix 2 and Helix 3 of PrPC and sterically blocks the structural conversion toward PrPSc. Poly-L-His, however, did not inhibit prion propagation in a prion-infected mouse when administered intraperitoneally, suggesting that the penetration of blood-brain barrier and/or the chemical stability of this polypeptide must be addressed before its application in vivo. Taken together, this study revealed the potential use of poly-L-His as a novel treatment against TSEs. (203 words).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Line, Tumor
  • Histidine / therapeutic use*
  • Humans
  • Magnetic Resonance Spectroscopy
  • Male
  • Mice
  • PrPC Proteins / metabolism
  • PrPSc Proteins / metabolism
  • Prion Diseases / drug therapy
  • Prion Diseases / metabolism
  • Prion Proteins / metabolism

Substances

  • PrPC Proteins
  • PrPSc Proteins
  • Prion Proteins
  • polyhistidine
  • Histidine

Grants and funding

Funding was received from the Japan Agency for Medical Research and Development (AMED; 17ek0109075h0003 to K.K.) and from the Japanese Ministry of Health, Labor, and Welfare Research Committee on Surveillance and Infection Control of Prion Disease (to K.K.).